These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19817743)

  • 1. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging.
    Lawrentschuk N; Haider MA; Daljeet N; Evans A; Toi A; Finelli A; Trachtenberg J; Zlotta A; Fleshner N
    BJU Int; 2010 May; 105(9):1231-6. PubMed ID: 19817743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
    Lawrentschuk N; Fleshner N
    BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
    Stewart CS; Leibovich BC; Weaver AL; Lieber MM
    J Urol; 2001 Jul; 166(1):86-91; discussion 91-2. PubMed ID: 11435830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
    D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
    J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
    BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.